Some studies have applied ratios of CD8+: FOXP3+ TILs to evaluate the prognostic effect of immune response in breast cancer, and reported that those with a ratio of CD8+: FOXP3+ TILs ≥1 had better survival than those with ratios <1 [21],[24],[43]. This evidence concerns the gene FOXP3 and breast carcinoma.